Welcome to our dedicated page for AI Maverick news (Ticker: AIMV), a resource for investors and traders seeking the latest updates and insights on AI Maverick stock.
AI Maverick Intel, Inc. reports developments tied to its OTC-traded AI platform business, including its completed rebranding from Bionoid Pharma and adoption of the AIMV trading symbol. Company updates describe its focus on using the AI Maverick platform for customer acquisition, partner-led deal flow, and revenue-scaling activities.
Recurring news themes include material agreements, strategic acquisition-right frameworks, shareholder voting matters, governance updates, capital-structure disclosures, operating and financial results, and regulatory disclosures connected to the company’s public-company status.
AI Maverick Intel (AIMV) issued 76,500,000 common shares to HEAL Group Holdings as the initial tranche under a Right of First Refusal Agreement effective February 11, 2026. The total ROFR consideration shares were adjusted to 100,000,000 for AIMV’s planned acquisition of HEAL Access Canada. AIMV also plans to seek an OTCQB Venture Market uplisting as part of its capital markets strategy.
AI Maverick Intel (AIMV) updated on HEAL Access Canada as it advances a proposed acquisition under a prior LOI. AIMV reports HEAL Access has >10 live customer implementations, 13 signed enterprise agreements, ~79 clinicians and ~118,000 connected patients across Canada, the UK, and the US.
The HEALix AI core supports clinical records, patient engagement, and case management with privacy frameworks (HIPAA, PHIPA, PIPEDA, GDPR). A definitive agreement remains subject to due diligence, final terms, and approvals.
AI Maverick Intel (AIMV) entered a non-binding LOI to acquire 100% of HEAL Access Canada (HAC) as the first transaction under a ROFR framework with HEAL.
Consideration would include 20,000,000 exchangeable AIMV shares and a secured vendor take-back note of ~USD$5.0 million; closing requires AIMV to have at least USD$5.0 million net positive working capital. Definitive agreement is targeted by May 29, 2026.
AI Maverick Intel (NASDAQ: AIMV) entered a Right of First Refusal agreement with HEAL Group Holdings effective February 11, 2026, giving AIMV the option to match third-party offers for certain HEAL assets during a defined exercise period.
AIMV will issue 120,000,000 common shares at a deemed price of US$0.02 per share (aggregate US$2.4 million) as consideration. The ROFR covers HEAL's AI-driven healthcare technology, services, and distribution businesses across more than six countries and remains in effect for three years unless mutually terminated.
AI Maverick Intel (OTC:AIMV) announced that effective Oct. 20, 2025 its common shares will trade under the new ticker AIMV following the company's rebranding from Bionoid Pharma to AI Maverick Intel.
The change aligns the market identity with the company's strategic focus on AI-driven customer acquisition, partner-led deal flow, and revenue acceleration via its AI Maverick platform. The company said its CUSIP and corporate structure remain unchanged and shareholders are not required to take any action. Management expects to finalize strategic JV initiatives in Q4 2025 to broaden commercialization and accelerate customer acquisition.